|
Oct 22
|
Gilead and MSD to advance once-weekly HIV treatment to Phase III
|
|
Oct 22
|
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
|
|
Oct 21
|
Gilead, MRK Report Data From Investigational Combination Study for HIV
|
|
Oct 21
|
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
|
|
Oct 19
|
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
|
|
Oct 19
|
Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE
|
|
Oct 18
|
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
|
|
Oct 18
|
Gilead withdraws bladder cancer drug in US after failed trial
|
|
Oct 18
|
High Growth Tech Stocks to Watch in October 2024
|
|
Oct 17
|
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
|
|
Oct 15
|
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
|
|
May 4
|
23 Most Profitable Stocks of the Last 12 Months
|
|
May 3
|
Forbes Has Listed Gilead as One of America’s Best Employers for Diversity
|
|
May 3
|
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
|
|
May 2
|
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
|
|
Apr 30
|
Gilead Sciences to Present at Upcoming Investor Conferences
|
|
Apr 30
|
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript
|
|
Apr 29
|
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
|
|
Apr 29
|
Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data
|
|
Jan 16
|
Gilead Sciences with Emma's Story: Self-Advocacy in Breast Cancer
|